Allergy Therapeutics plc

Equities

AGY

GB00B02LCQ05

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:10 2024-05-23 EDT			5-day change	1st Jan Change
3.4 ^GBX	+3.03%		+1.49%	+36.00%

05-07	Abingdon Health buys IVDeology Holdings	AN
05-07	Allergy Therapeutics plc Provides Further Details from Positive Top Line Results from G306 Phase III Field Study G306 to Evaluate the Efficacy and Safety of Grass MATA MPL	CI

Allergy Therapeutics plc Provides Revenue Guidance for the Year Ended 30 June 2020

June 24, 2020 at 02:00 am

Allergy Therapeutics plc provided revenue guidance for the year ended 30 June 2020. Reported revenues for the year ended 30 June 2020 are expected to be at least 4% ahead of last year in constant currency terms.

Latest news about Allergy Therapeutics plc

Abingdon Health buys IVDeology Holdings	05-07	AN
Allergy Therapeutics plc Provides Further Details from Positive Top Line Results from G306 Phase III Field Study G306 to Evaluate the Efficacy and Safety of Grass MATA MPL	05-07	CI
Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director	04-03	CI
EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line	03-27	AN
Allergy Therapeutics Gets OK to Draw Down GBP15 Million From Amended Loan Facility	03-27	MT
AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue	03-27	AN
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Reports Fiscal H1 Revenue GBP33.6M	03-27	MT
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Posts Fiscal H1 Loss GBX-0.58	03-27	MT
Allergy Therapeutics plc Provides Sales Guidance for the Second Half and Full Year Ending on 30 June 2024	03-27	CI
Allergy Therapeutics plc Reports Earnings Results for the Half Year Ended December 31, 2023	03-27	CI
Allergy Therapeutics starts dosing patients in peanut allergy trial	03-12	AN
Allergy Therapeutics Announces Commencement of Subcutaneous Dosing of Peanut Allergic Patients in the Phase I/IIa PROTECT Trial Evaluating its Novel Virus-Like Particle Based Peanut Allergy Vaccine Candidate	03-12	CI
Allergy Therapeutics plc Announces Appointment of Shaun Furlong to Board of Directors	03-11	CI
Allergy Therapeutics forecasts revenue drop but trials going well	02-14	AN
Alliance Pharma appoints chair; FireAngel sales down	02-05	AN
Scancell's Chief Development Officer to Step Down	02-05	MT
Allergy Therapeutics resumes trading on AIM; annual revenue plunges	01-30	AN
Allergy Therapeutics amends facility, plans warrant issue	12-27	AN
Allergy Therapeutics Agrees Amendment to Loan Facility	12-27	MT
EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens	12-15	AN
Allergy Therapeutics' Allergic Rhinoconjunctivitis Treatment Returns Positive Data in Late-stage Trial	12-13	MT
Allergy Therapeutics shares jump as hails grass allergy jab data	12-13	AN
AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer	12-13	AN
Allergy Therapeutics plc Provides an Update on the Data Analysis of Its Pivotal G306 Phase III Trial of Grass MATA MPL	12-13	CI
Allergy Therapeutics in Advanced Talks for Potential Funding; Shares Drop	12-11	MT

Chart Allergy Therapeutics plc

Duration

Period

More charts

Company Profile

Allergy Therapeutics plc is a United Kingdom-based integrated specialty pharmaceutical company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.

Sector

Biotechnology & Medical Research

Calendar

2024-09-24 - Q4 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ALLERGY THERAPEUTICS PLC	+36.00%	200M
VERTEX PHARMACEUTICALS INCORPORATED	+10.60%	115B
REGENERON PHARMACEUTICALS, INC.	+12.13%	106B
BIONTECH SE	-4.39%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.01%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.60%	14.03B
SAREPTA THERAPEUTICS, INC.	+30.97%	12.13B

Bio Therapeutic Drugs